Latest Arry Stories
Array BioPharma Inc. (NASDAQ: ARRY) today reported financial results for the first quarter of fiscal 2009. Array reported revenue of $5.7 million for the first quarter of fiscal 2009, compared to revenue of $6.6 million for the same period in fiscal 2008.
Array BioPharma has announced positive results from a Phase II acute inflammatory dental pain study evaluating the analgesic efficacy of ARRY-797, a small molecule p38 inhibitor.
Array BioPharma, a biopharmaceutical company, has reported positive preclinical data of a novel small molecule glucokinase activator, ARRY-403, a drug for the treatment of Type 2 diabetes.
- A political dynamiter.